Last edition
News about Global Pharma
Cerapedics Receives FDA Approval for PearlMatrix Bone Graft
Cerapedics Inc. announced the U.S. Food and Drug Administration (FDA) premarket approval (PMA) of PearlMatrix™ P-15 Peptide Enhanced Bone Graft as a Class III drug-device combination product for use in single-level transforminal lumbar interbody fusion (TLIF) surgery in adult patients with degenerative disc disease (DDD).
Global Pharma | 24/06/2025 | By Manvi | 921
Glenmark Launches TEVIMBRA in India for Lung and Esophageal Cancer Treatment
Glenmark Pharmaceuticals has launched TEVIMBRA (tislelizumab) in India, marking its entry into immuno-oncology with a globally approved PD-1 inhibitor for advanced lung and esophageal cancers.
Global Pharma | 24/06/2025 | By Manvi | 231
PharmaJet, Immuno Cure Partner for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
PharmaJet has partnered with Immuno Cure to provide its needle-free Tropis ID system for delivering ICVAX, a novel therapeutic HIV-1 DNA vaccine, in a human clinical trial—aiming to enhance vaccine performance and patient experience while advancing toward a functional HIV cure.
Global Pharma | 23/06/2025 | By Manvi | 138
IONETIX and AlfaRim Announce Strategic Collaboration on Cyclotron-Produced Actinium-225
IONETIX and AlfaRim announced a strategic collaboration to commercialize cyclotron-produced actinium-225, a key isotope enabling next-generation targeted alpha therapies (TATs).
Global Pharma | 23/06/2025 | By Manvi | 275
Under the agreement, TerraPower Isotopes would supply Ratio with quantities of non-cGMP Ac-225 for use to incorporate into or use in the development of Ratio's radiopharmaceuticals.
Global Pharma | 21/06/2025 | By Manvi | 185
Catalyst MedTech Named Exclusive US Distributor of CareMiBrain
Catalyst MedTech has announced it will serve as the exclusive US distributor of CareMiBrain™, an ultra-high resolution dedicated brain PET system developed by MindView / OncoVision.
Global Pharma | 21/06/2025 | By Manvi | 112
Palvella Therapeutics Secures US Patent for QTORIN Rapamycin
Palvella Therapeutics has secured its sixth US patent for QTORIN 3.9 percent rapamycin gel, strengthening intellectual property protection around its lead candidate for rare genetic skin diseases with no approved FDA therapies.
Global Pharma | 21/06/2025 | By Manvi | 178
FDA Clears Happy Ring as Class II Device for At-Home Sleep Disorder Diagnosis
Through the company's Happy Sleep platform, individuals order a sleep test online, wear the ring overnight, and review the results with a board-certified sleep physician – all in the comfort of their own home.
Global Pharma | 20/06/2025 | By Manvi | 443
Advanced Wellness Center Debuts Cutting-Edge Muscle Activation for Fat Loss and Recovery
Advanced Wellness Center is one of the first health centers in the area to offer leading-edge, noninvasive technology using muscle activation to build muscle, burn fat, help with muscle injury and recovery, and strengthen the pelvic floor.
Global Pharma | 20/06/2025 | By Manvi | 161
Pierre Fabre Laboratories has acquired global rights to two next-generation EGFR inhibitors – PFL-721 and PFL-241 – from Antares Therapeutics, strengthening its oncology pipeline with precision therapies targeting non-small cell lung cancer.
Global Pharma | 20/06/2025 | By Manvi | 233
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy